Neogenomics.com Website Review

QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs A New Level of Service for Diagnosing Hematologic Malignancies NeoCOMPLETE™ Now also available through NEOGENOMICS - for unclear or unknown diagnoses in solid tumors NeoGenomics offers lab services for oncology clinical trials NeoGenomics offers lab services for oncology clinical trials NeoGenomics Appoints Dr. Lawrence M. Weiss as Chief Scientific Officer NeoGenomics Reports 17% Revenue Growth to Record $69 Million Read press release NeoGenomics makes billing as flexible as possible by providing many different payment options. NeoGenomics Announces Participation in NCI-MATCH Clinical Trial NeoGenomics Awarded Clinical Reference Laboratory Testing Services Agreement with Premier Learn about our unique service offerings that are now available globally Read our Article in Springer Nature Detecting BRAF, KRAS, and EGFR Mutations via NGS vs. PCR-based Kits FISH for Burkitt-like lymphoma with 11q aberration Learn more For diagnosis of T-cell lymphomas of follicular helper T-cell origin Learn more Useful in dx of brain tumors, MPNST, melanoma, and breast malignancy Learn more FISH for Burkitt-like lymhoma with 11q aberration Learn more Minimal residual disease detection for treatment and prognosis Learn more Review and print test descriptions, specimen requirements, turnaround times, CPT codes, and other test information here.  Ewing sarcoma; Primitive neuroectodemal tumor (PNET) t(11;22)(q24;q12) Myoepithelial tumor of soft tissue and bone t(6;22)(p21;q12) Undifferentiated small round blue cell tumor t(4;19)(q35;q13) The NeoTYPE Liposarcoma Fusion Profile combines next-generation sequencing to detect translocations in the genes EWSR1, FUS, HMGA2, PLAG1, plus their fusion partners. Additionally, FISH testing for MDM2 to detect amplifications relevant in liposarcoma is also performed.